Imipenem/cilastatin/relebactam
| Combination of | |
|---|---|
| Imipenem | β-Lactam antibiotic |
| Cilastatin | Dehydropeptidase inhibitor |
| Relebactam | β-Lactamase inhibitor |
| Clinical data | |
| Trade names | Recarbrio |
| Other names | MK-7655A |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a619046 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Imipenem/cilastatin/relebactam (Recarbrio) is a drug combination used as an antibiotic. In 2019, the United States approved it for complicated urinary tract and complicated intra-abdominal infections.[1][2][3]
History
The FDA granted Qualified Infectious Disease Product (QIDP) designation and priority review to Recarbrio.[1] The FDA granted the approval of Recarbrio to Merck & Co., Inc.[1]
See also
References
- ^ a b c "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". U.S. Food and Drug Administration (FDA) (Press release). 17 July 2019. Archived from the original on 20 November 2019. Retrieved 20 November 2019.
This article incorporates text from this source, which is in the public domain.
- ^ "Drug Trial Snapshot: Recarbrio". U.S. Food and Drug Administration (FDA). 2 August 2019. Archived from the original on 20 November 2019. Retrieved 20 November 2019.} This article incorporates text from this source, which is in the public domain.
- ^ "Recarbrio (imipenem, cilastatin, and relebactam) FDA Approval History". Drugs.com. 21 July 2019. Retrieved 20 November 2019.
External links
- "Drug Approval Package: Recarbrio". U.S. Food and Drug Administration (FDA).</ref>
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |